We still have not gapped and went, so I would think that possibility is lowering but I would not completely discount it. We have some positive news today in the.
The sector has gapped above the range with merger Monday. Interestingly the last gap we saw in the XBI (JPM week) saw a gap and run instead of a test.
Sarepta Therapeutics (SRPT) has a long history with several inflection points through the years. Moving upward from a penny stock back in the days they used to be called AVI.
Resistance is acting like resistance. It looked early that we might be peaking above it but clearly that is not the case. These sort of false breakouts (and breakdowns) are.
Not surprisingly we are in a post earnings lull. While there are still earnings being posted, the bulk of the major ones have been reported. We are also seeing the.
We have some interesting news today (positive and negative) with some interesting read through. I still think the base case is that the sector is in a range until proven.
The sector faded yesterday and seems to be in a little range between $80 and $86. This is not necessarily a bad thing after the big bounce we had. Sitting.
The sector seems to have gotten its footing in a way I was not expecting. Perhaps there is a bigger underlying bid than I thought. Perhaps the dovish turn in.
Another day and another weak earning for biotech. This was fairly predictable and the real question is how far these earnings (and the upcoming slew of secondaries now that the.
An interesting start to large cap earnings. The sector was weak yesterday and this could be the long awaited pullback (or another head fake). Ideally, the pullback bottoms out in.
Another day and another chance to grind away at these levels. Yesterday was pretty weak and it will be interesting to see how the sector reacts. If we have an.
Certainly not the best start to the week but it remains early. As long as the XBI remains above $80 I would not worry too much about this being the.